Clinical Trials
Since our beginning, we have been on the cutting edge of advances in treating some very common eye conditions. We have been involved in clinical trials that have led to approval of three major treatments for wet age-related macular degeneration, and we are now enrolling or will soon begin to enroll patients in three more studies.
Below is a list of all the studies which Retina Specialists are participating or have participated at Retina Specialists. Please call our office at 410-296-9748 for more information.
Current Studies
Age-related Macular Degeneration (Wet - Neovascularization)
| Ascent | Phase III | Follow-Up |
| RGX-314-5101( Follow-up) | Phase II | RECRUITING |
| PORTAL/Roche | Open Label Ext. | Follow Up |
| Lugano | Phase III | Follow Up |
| Sol-R | Phase III | Follow Up |
| M24-528 | Phase III b | Upcoming |
| Sanofi | Phase 1/2 | Upcoming |
Age Related Macular Degeneration (Dry-Geographic Atrophy)
| Parasol | Phase II b | Follow Up |
| Parasol | follow up-Phase II b | Follow Up |
| Gallop | Phase II | Upcoming |
| Honu | Observational | Follow Up |
| Reveal | Observational | RECRUITING |
Diabetic Macular Edema
| Borolo | Phase 2/3 | Follow Up |
| Pagoda/Roche | Phase III | Follow Up |
| Como | Phase III | Upcoming |
PREVIOUS CLINICAL TRIALS:
Macular Degeneration (Wet)
| LADDER/Roche | Phase II |
| Cedar/Allergan | Phase III |
| OPT-302-1002/Opthea | Phase IIb |
| CAPELLA/Regeneron | Phase II |
| MAKO/Ohr | Phase III |
| SOLARIS/Ophthotech | Phase III |
| NEXUS/Lpath | Phase II |
| CATT Follow-up/ National Eye Institute | Comparative Trial |
| VIEW-1 Extension/Regeneron | Phase III |
| CATT/National Eye Institute | Comparative Trial |
| COBALT/OPKO | Phase III |
| LEVEL/OSI – EyeTech | Phase IV |
| HORIZON/Genentech | Open Label |
| SAILOR/Genentech | Phase IIIb |
| ACUITY | Phase I |
| CARE/Acuity | Phase II |
| GENAERA 208/209 | Phase II |
| GENAERA 301 | Phase III |
| MARINA/Genentech | Phase III |
| ANCHOR/Genentech | Phase III |
| LUCERNE/Roche | Phase III |
| ARCHWAY/Roche | Phase III |
Macular Degeneration (Dry)
| CLG561-2201/Alcon | Proof of Concept |
| LAMPALIZUMAB/Genentech | Phase III |
| OMASPECT/Genentech | Extension Study |
| BAM114341/GlaxoSmithKline | Phase II |
| ISIS 696844-CS5/Ionis | Phase II |
| Derby/Apellis | Phase III |
Diabetic Retinopathy
| MYL1701P-300/Mylan GmbH | Biosimilar |
| PANORAMA/Regeneron | Phase III |
| LUMINATE/Allegro | Phase II |
| RISE/Genentech | Phase III |
| DIAMOND/Macusight | Phase II |
| PKC (MBDV)/Eli Lilly | Open Label |
| PKC (MBCM)/Eli Lilly | Phase III |
| RACE/Acuity | Phase II |
| Rhine/Roche | Phase III |
| Pavilion/Roche | Phase III |
Nonclearing Vitreous Hemorrhage
| Hyaluronidase/Advanced Corneal | Phase III |
| Hyaluronidase/Advanced Corneal | Phase II |
Retinal Vein Occlusions
| TOPAZ/Clearside Biomedical | Phase III |
| COPERNICUS/Regeneron | Phase III |
| VIBRANT/Regeneron | Phase III |
| Posurdex Study/Allergan | Phase III |
Click on this link for more information, and please contact our clinical coordinators at 410-296-9748 if you are interested in learning more about the latest clinical studies.
Institutional Biosafety Committee (IBC) Meeting minutes
RGX-314-3101 - Click here to view meeting minutes from June 30, 2025